Elias Wagner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5816354/publications.pdf

Version: 2024-02-01

840776 752698 22 428 11 20 citations h-index g-index papers 23 23 23 417 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review. Translational Psychiatry, 2021, 11, 487.	4.8	61
2	Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia —Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophrenia Bulletin, 2020, 46, 1459-1470.	4.3	58
3	Clozapine augmentation strategies $\hat{a}\in\hat{a}$ a systematic meta-review of available evidence. Treatment options for clozapine resistance. Journal of Psychopharmacology, 2019, 33, 423-435.	4.0	52
4	Impact of smoking behavior on clozapine blood levels – a systematic review and metaâ€analysis. Acta Psychiatrica Scandinavica, 2020, 142, 456-466.	4.5	49
5	Clozapine levels as a predictor for therapeutic response: A systematic review and metaâ€analysis. Acta Psychiatrica Scandinavica, 2021, 144, 422-432.	4.5	29
6	Characteristics and definitions of ultra-treatment-resistant schizophrenia – A systematic review and meta-analysis. Schizophrenia Research, 2021, 228, 218-226.	2.0	28
7	rTMS and tDCS for the treatment of catatonia: A systematic review. Schizophrenia Research, 2020, 222, 73-78.	2.0	21
8	Efficacy of high-frequency repetitive transcranial magnetic stimulation in schizophrenia patients with treatment-resistant negative symptoms treated with clozapine. Schizophrenia Research, 2019, 208, 370-376.	2.0	19
9	Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial. Contemporary Clinical Trials Communications, 2020, 17, 100537.	1.1	17
10	Concomitant drug abuse of opioid dependent patients in maintenance treatment detected with a multiâ€ŧarget screening of oral fluid. American Journal on Addictions, 2018, 27, 407-412.	1.4	15
11	Cerebrospinal Fluid Pathologies in Schizophrenia-Spectrum Disorder—A Retrospective Chart Review. Schizophrenia Bulletin, 2022, 48, 47-55.	4.3	12
12	Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders. Translational Psychiatry, 2022, 12, 145.	4.8	12
13	Repetitive transcranial magnetic stimulation (rTMS) for schizophrenia patients treated with clozapine. World Journal of Biological Psychiatry, 2021, 22, 14-26.	2.6	11
14	Cognitive and functional deficits are associated with white matter abnormalities in two independent cohorts of patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 957-969.	3.2	10
15	rTMS for clozapine refractory schizophrenia – A systematic review and pairwise meta-analysis. Schizophrenia Research, 2019, 211, 113-114.	2.0	8
16	Psychotropic drugs for the treatment of non-suicidal self-injury in children and adolescents: a systematic review and meta-analysis. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1559-1568.	3.2	7
17	Cerebrospinal fluid abnormalities in first- and multi-episode schizophrenia-spectrum disorders: impact of clinical and demographical variables. Translational Psychiatry, 2021, 11, 621.	4.8	5
18	Classical blood biomarkers identify patients with higher risk for relapse 6Âmonths after alcohol withdrawal treatment. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 891-902.	3.2	4

#	Article	IF	CITATION
19	Association between aerobic fitness and the functional connectome in patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1253-1272.	3.2	4
20	Effects of Smoking Status on Remission and Metabolic and Cognitive Outcomes in Schizophrenia Patients Treated with Clozapine. Pharmacopsychiatry, 2020, 53, 273-283.	3.3	2
21	Effects of high-frequency prefrontal rTMS on heart frequency rates and blood pressure in schizophrenia. Journal of Psychiatric Research, 2021, 140, 243-249.	3.1	2
22	60 Years of Combining Tranylcypromine. Journal of Clinical Psychopharmacology, 2022, 42, 51-70.	1.4	1